tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ABBV Stock Latest News

AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch
Company AnnouncementsAbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch
9h ago
ABBV
AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
PremiumCompany Announcements
AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
1d ago
ABBV
AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
PremiumCompany Announcements
AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
2d ago
ABBV
AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
PremiumCompany Announcements
AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
3d ago
ABBV
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
PremiumRatings
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
8d ago
ABBV
AbbVie’s Real-World RINVOQ Data in Japan: What It Means for Ankylosing Spondylitis Investors
PremiumCompany AnnouncementsAbbVie’s Real-World RINVOQ Data in Japan: What It Means for Ankylosing Spondylitis Investors
8d ago
ABBV
AbbVie price target lowered to $230 from $240 at UBS
Premium
The Fly
AbbVie price target lowered to $230 from $240 at UBS
9d ago
ABBV
AbbVie Earnings Call: New Growth Engines Take Lead
Premium
Company Announcements
AbbVie Earnings Call: New Growth Engines Take Lead
9d ago
ABBV
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
PremiumRatings
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
9d ago
ABBV
AbbVie price target lowered to $228 from $232 at Evercore ISI
PremiumThe Fly
AbbVie price target lowered to $228 from $232 at Evercore ISI
9d ago
ABBV
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
PremiumThe Fly
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
9d ago
GSK
ABBV
Midday Fly By: AMD falls despite Q4 beat, Uber reports mixed results
PremiumThe Fly
Midday Fly By: AMD falls despite Q4 beat, Uber reports mixed results
9d ago
F
AMD
AbbVie says ‘plenty of capacity’ to invest in internal and external innovation
PremiumThe FlyAbbVie says ‘plenty of capacity’ to invest in internal and external innovation
9d ago
ABBV
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
Premium
The Fly
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
9d ago
ABBV
AbbVie sees Q1 adjusted EPS $2.97-$3.01, consensus $3.10
Premium
The Fly
AbbVie sees Q1 adjusted EPS $2.97-$3.01, consensus $3.10
9d ago
ABBV
AbbVie sees FY26 revenue about $67B, consensus $66.95B
PremiumThe Fly
AbbVie sees FY26 revenue about $67B, consensus $66.95B
9d ago
ABBV
AbbVie says aesthetics growth ‘will remain challenged’ in 2026
PremiumThe Fly
AbbVie says aesthetics growth ‘will remain challenged’ in 2026
9d ago
ABBV
AbbVie says entering 2026 with ‘substantial momentum’
PremiumThe Fly
AbbVie says entering 2026 with ‘substantial momentum’
9d ago
ABBV
AbbVie sees FY26 revenue growth of 9.5%
PremiumThe Fly
AbbVie sees FY26 revenue growth of 9.5%
9d ago
ABBV
Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results
PremiumThe FlyMorning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results
9d ago
AMD
BSX
AbbVie reports Q4 adjusted EPS $2.71, consensus $2.65
Premium
The Fly
AbbVie reports Q4 adjusted EPS $2.71, consensus $2.65
10d ago
ABBV
AbbVie sees FY26 adjusted EPS $14.37-$14.57, consensus $14.22
Premium
The Fly
AbbVie sees FY26 adjusted EPS $14.37-$14.57, consensus $14.22
10d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >